| |  Online-Ressource |
|---|
| Verfasst von: | Sikic, Danijel [VerfasserIn]  |
|---|
| | Eckstein, Markus [VerfasserIn] |
|---|
| | Weyerer, Veronika [VerfasserIn] |
|---|
| | Kubon, Jennifer [VerfasserIn] |
|---|
| | Breyer, Johannes [VerfasserIn] |
|---|
| | Roghmann, Florian [VerfasserIn] |
|---|
| | Kunath, Frank [VerfasserIn] |
|---|
| | Keck, Bastian [VerfasserIn] |
|---|
| | Erben, Philipp [VerfasserIn] |
|---|
| | Hartmann, Arndt [VerfasserIn] |
|---|
| | Wirtz, Ralph M. [VerfasserIn] |
|---|
| | Wullich, Bernd [VerfasserIn] |
|---|
| | Taubert, Helge [VerfasserIn] |
|---|
| | Wach, Sven [VerfasserIn] |
|---|
| Titel: | High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer |
|---|
| Titelzusatz: | laboratory-bladder cancer |
|---|
| Verf.angabe: | Danijel Sikic, Markus Eckstein, Veronika Weyerer, Jennifer Kubon, Johannes Breyer, Florian Roghmann, Frank Kunath, Bastian Keck, Philipp Erben, Arndt Hartmann, Ralph M. Wirtz, Bernd Wullich, Helge Taubert, Sven Wach |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | February 2022 |
|---|
| Umfang: | 10 S. |
|---|
| Fussnoten: | Online verfügbar: 28. Juli 2021, Artikelversion: 29. Januar 2022 ; Gesehen am 27.05.2024 |
|---|
| Titel Quelle: | Enthalten in: Urologic oncology |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1995 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 40(2022), 2 vom: Feb., Seite 63.e9-63.e18 |
|---|
| ISSN Quelle: | 1873-2496 |
|---|
| Abstract: | Introduction - Molecular markers associated with breast cancer are assumed to be associated with outcome in non-muscle-invasive bladder cancer (NMIBC). - Materials and methods - We retrospectively investigated the association of the mRNA expression of estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR), MKI67, and HER2 (ERBB2) with recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) in 80 patients with stage T1 NMIBC. - Results - High expression of ESR2 (P=0.003), ERBB2 (P < 0.001), and MKI67 (P=0.029) was associated with shorter RFS. Only high ERBB2 was an independent prognostic factor for reduced RFS (HR=2.98; P=0.009). When sub stratifying the cohort, high ESR2 was associated with reduced RFS (P < 0.001), CSS (P=0.037) and OS (P=0.006) in patients without instillation therapy. High ESR2 was associated with reduced CSS (P=0.018) and OS (P=0.029) in females and with shorter RFS in both sexes (males: P=0.035; females: P=0.010). Patients with high ERBB2 showed reduced CSS (P=0.011) and OS (P=0.042) in females and reduced CSS (P=0.012) in those without instillation, while RFS was significantly reduced irrespective of sex or instillation. - Conclusion - High mRNA expression of ERBB2 is an independent predictor of reduced RFS in patients with stage T1 NMIBC. High ERBB2 and ESR2 are associated with reduced outcomes, especially in females and patients without instillation therapy. |
|---|
| DOI: | doi:10.1016/j.urolonc.2021.06.021 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.urolonc.2021.06.021 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S1078143921002970 |
|---|
| | DOI: https://doi.org/10.1016/j.urolonc.2021.06.021 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | ERBB2 |
|---|
| | Estrogen receptor |
|---|
| | HER2 |
|---|
| | Non-muscle-invasive bladder cancer |
|---|
| | Urothelial carcinoma |
|---|
| K10plus-PPN: | 1889903523 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer / Sikic, Danijel [VerfasserIn]; February 2022 (Online-Ressource)
